| Literature DB >> 33553688 |
Albert Z Luu1,2, Vincent Z Luu1,2, Biswajit Chowdhury1, Andrew Kosmopoulos1, Yi Pan1, Mohammed Al-Omran2,3,4, Adrian Quan1, Hwee Teoh1,5, David A Hess2,3,6,7, Subodh Verma1,2,4.
Abstract
Doxorubicin (DOX) is an effective, broad-spectrum antineoplastic agent with serious cardiotoxic side effects, which may lead to the development of heart failure. Current strategies to diagnose, prevent, and treat DOX-induced cardiotoxicity (DIC) are inadequate. Recent evidence has linked the dysregulation and destruction of the vascular endothelium to the development of DIC. Autophagy is a conserved pro-survival mechanism that recycles and removes damaged sub-cellular components. Autophagy-related protein 7 (ATG7) catalyzes autophagosome formation, a critical step in autophagy. In this study, we used endothelial cell-specific Atg7 knockout (EC-Atg7 -/- ) mice to characterize the role of endothelial cell-specific autophagy in DIC. DOX-treated EC-Atg7 -/- mice showed reduced survival and a greater decline in cardiac function compared to wild-type controls. Histological assessments revealed increased cardiac fibrosis in DOX-treated EC-Atg7 -/- mice. Furthermore, DOX-treated EC-Atg7 -/- mice had elevated serum levels of creatine kinase-myocardial band, a biomarker for cardiac damage. Thus, the lack of EC-specific autophagy exacerbated DIC. Future studies on the relationship between EC-specific autophagy and DIC could establish the importance of endothelium protection in preventing DIC.Entities:
Keywords: Autophagy; Cardiomyopathy; Doxorubicin; Endothelium; Heart failure
Year: 2021 PMID: 33553688 PMCID: PMC7851775 DOI: 10.1016/j.bbrep.2021.100926
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Fig. 1Loss of ATG7 protein expression in lung ECs of mice. Representative co-immunofluorescence images of the lung sections (transverse) for WT (left) and EC-Atg7 (right) mice. CD31 (green), ATG7 (red), and 4′,6-diamidino-2-phenylindole (DAPI) (blue) were simultaneously detected (top to bottom). ATG7 was detected in CD31+ cells of WT mice. In contrast, ATG7 was not detected in CD31+ cells from EC-Atg7 mice. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2Reduced survival and cardiac function in DOX-treated mice. (A) Kaplan-Meier survival curves for WT and EC-Atg7 mice after DOX (20 mg/kg) treatment. WT mice survived longer than EC-Atg7 mice (p < 0.05 using the log-rank test). (B) Left ventricular ejection fraction (LVEF) and (C) Left ventricular fractional shortening (LVFS) in WT (n = 9) and EC-Atg7 (n = 9) mice at baseline and 3 days post-DOX treatment. DOX-treated EC-Atg7 mice had reduced LVEF and LVFS compared to their WT littermates. Data are presented as mean ± SD. *p < 0.05 using two-way ANOVA and the Tukey test.
Fig. 3DOX-treated mice demonstrated increased cardiomyocyte vacuolization. (A) Representative hematoxylin and eosin (H&E) images showing the left ventricles (LV) of WT (top) and EC-Atg7 (bottom) mice three days after SAL (0.9% NaCl) (left) or DOX (20 mg/kg) (right) treatment. The pink and blue areas represent the cytoplasm and nucleus, respectively. (B) Quantification of vacuole number in the LV of WT and EC-Atg7 mice (3 slides/mouse) three days after SAL (n = 5/group) or DOX (n = 5/group) treatment. DOX-treated mice showed increased vacuoles compared to SAL-treated mice. There was no difference in the total number of vacuoles observed between DOX-treated WT and EC-Atg7 mice. Data are presented as mean ± SD. *p < 0.05 using two-way ANOVA followed by Tukey's multiple comparison tests. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 4DOX-treated mice demonstrated increased cardiac fibrosis and serum CK-MB. (A) Representative images showing the left ventricle (LV) from WT (top) and EC-Atg7 (bottom) mice stained with Masson's trichrome at 3 days after SAL (0.9% NaCl) (left) or DOX (20 mg/kg) (right) treatment. The dark-blue and red areas represent collagen deposition and the cell cytoplasm, respectively. (B) Blinded scoring of cardiac fibrosis though semi-quantification of the extent of collagen deposition in the LV of WT and EC-Atg7 mice (1 slide/mouse) three days after SAL (n = 5/group) or DOX (n = 5/group) treatment. DOX-treated mice showed increased cardiac fibrosis compared to SAL-treated animals. In addition, DOX-treated EC-Atg7 mice demonstrated increased cardiac fibrosis compared to DOX-treated WT mice. (C) CK-MB levels in the sera of SAL- or DOX-treated WT (n = 5) and EC-Atg7 (n = 5) mice were measured by ELISA assays. DOX-treated EC-Atg7 mice demonstrated increased serum CK-MB compared to DOX-treated WT mice. Data are mean ± SD. *p < 0.05 using two-way ANOVA and the Tukey test. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)